Liste modèle des médicaments essentiels

Abemaciclib

Section	Indications
Targeted therapies	Therapeutic equivalent to palbociclib pour Other specified malignant neoplasms of breast

Abiraterone

Section	Indications
Hormones and antihormones ◦ Oral > Solid: 250 mg; 500 mg	Malignant neoplasms of prostate

Adalimumab

Section	Indications
Immunomodulators for non-malignant disease ◦ Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL	Axial spondyloarthritis Crohn disease site Rheumatoid arthritis

Afatinib

Section	Indications
Targeted therapies	Therapeutic equivalent to erlotinib pour Other specified malignant neoplasms of bronchus or lung

All-trans retinoic acid

Section	Indications
Targeted therapies ◦ Oral > Solid: 10 mg capsule	Acute myeloid leukaemia with recurrent genetic abnormalities

Allopurinol

Section	Indications
Supportive medicines ◦ Parenteral > General injections > IV: 500 mg (as sodium) powder for injection ◦ Oral > Solid: 100 mg; 300 mg	Tumour lysis syndrome

Anastrozole

Section	Indications
Hormones and antihormones ◦ Oral > Solid: 1 mg tablet	Malignant neoplasms of breast Other specified malignant neoplasms of breast

Arsenic trioxide

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion	Acute myeloid leukaemia with recurrent genetic abnormalities

Asparaginase

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > unspecified: 10000 IU in vial powder for injection ◦ Powder for injection: 10 000 IU in vial.	Lymphoid leukaemia, not elsewhere classified Unspecified malignant neoplasms of unspecified sites

Atezolizumab

Section	Indications
Immunomodulators ◦ Parenteral > General injections > IV: 840 mg per 14 mL in vial concentrate for solution for infusion; 1200 mg per 20 mL in vial concentrate for solution for infusion ◦ Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion	Therapeutic equivalent to pembrolizumab pour Adenocarcinoma of stomach Hepatocellular carcinoma of liver Therapeutic equivalent to pembrolizumab pour Other specified malignant neoplasms of bronchus or lung Other specified malignant neoplasms of bronchus or lung

Axicabtagene ciloleucel

Section	Indications
Antineoplastics and supportive medicines ◦ Cell suspension for infusion: 2 × 10*6 anti-CD19 CAR-positive viable T-cells per kg of body weight.	Diffuse large B-cell lymphomas

Axitinib

Section	Indications
Targeted therapies ◦ Oral > Solid > tablet: 1 mg; 3 mg; 5 mg	Renal cell carcinoma of kidney, except renal pelvis

Azacitidine

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 100 mg in vial powder for injection	Myeloid leukaemia

Azathioprine

Section	Indications
Immunomodulators for non-malignant disease ◦ Oral > Solid > tablet: 50 mg (scored) ◦ Parenteral > General injections > IV: 50 mg in vial powder for injection (as sodium salt); 100 mg in vial powder for injection (as sodium salt) ◦ Oral > Liquid: 10 mg per mL ◦ Oral > Solid > tablet: 25 mg; 50 mg (scored)	Relapsing-remitting multiple sclerosis Failure or rejection of transplanted organs or tissues

Bendamustine

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL	Chronic lymphocytic leukaemia or small lymphocytic lymphoma Follicular lymphoma

Bevacizumab

Section	Indications
Immunomodulators ◦ Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion; 25 mg per mL in 16 mL vial concentrate for solution for infusion	Hepatocellular carcinoma of liver

Bicalutamide

Section	Indications
Hormones and antihormones ◦ Oral > Solid: 50 mg	Malignant neoplasms of prostate

Binimetinib

Section	Indications
Targeted therapies	Therapeutic equivalent to trametinib pour Other specified melanoma of skin

Bleomycin

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)	Kaposi sarcoma of unspecified primary site Germ cell tumour of testis Other specified malignant neoplasms of the ovary Unspecified malignant neoplasms of unspecified sites Hodgkin lymphoma

Blinatumomab

Section	Indications
Immunomodulators ◦ Parenteral > General injections > IV: 35 µg in vial; 38.5 µg in vial	B lymphoblastic leukaemia or lymphoma, not elsewhere classified

Bortezomib

Section	Indications
Targeted therapies ◦ Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection	Plasma cell myeloma

Calcium folinate (leucovorin calcium)

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule; 7.5 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule ◦ Oral > Solid > tablet: 15 mg; 5 mg; 25 mg ◦ Oral > Solid: 15 mg tablet ◦ Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule	Burkitt lymphoma including Burkitt leukaemia Osteosarcoma of bone or articular cartilage of unspecified sites Malignant neoplasms of rectum Malignant neoplasm metastasis in large intestine Malignant neoplasms of colon Unspecified malignant neoplasms of unspecified sites Malignant trophoblastic neoplasms of placenta

Capecitabine

Section	Indications
Cytotoxic medicines ◦ Oral > Solid > tablet: 150 mg; 500 mg	Malignant neoplasms of rectum Malignant neoplasm metastasis in large intestine Malignant neoplasms of colon Other specified malignant neoplasms of breast

Carboplatin

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL	Other specified gliomas of brain Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx Malignant neoplasms of cervix uteri Malignant neoplasms of hypopharynx Malignant neoplasms of nasopharynx Malignant neoplasms of oropharynx Osteosarcoma of bone or articular cartilage of unspecified sites Other specified malignant neoplasms of the ovary Germ cell tumour of testis Malignant neoplasms of nasopharynx Other specified carcinomas of ovary Other specified malignant neoplasms of bronchus or lung Malignant neoplasms of breast Retinoblastoma Malignant neoplasms of kidney, except renal pelvis

Cemiplimab

Section	Indications
Immunomodulators ◦ Parenteral > General injections > IV: 50 mg per mL in 7 mL vial concentrate for solution for infusion	Therapeutic equivalent to pembrolizumab pour Adenocarcinoma of stomach Therapeutic equivalent to pembrolizumab pour Other specified malignant neoplasms of bronchus or lung Other specified malignant neoplasms of bronchus or lung

Certolizumab pegol

Section	Indications
Immunomodulators for non-malignant disease	Therapeutic equivalent to adalimumab pour Axial spondyloarthritis Therapeutic equivalent to adalimumab pour Crohn disease site Therapeutic equivalent to adalimumab pour Rheumatoid arthritis

Chlorambucil

Section	Indications
Cytotoxic medicines ◦ Oral > Solid: 2 mg tablet	Chronic lymphocytic leukaemia or small lymphocytic lymphoma Unspecified malignant neoplasms of unspecified sites

Ciclosporin

Section	Indications
Immunomodulators for non-malignant disease ◦ Parenteral > General injections > IV: 50 mg per mL in 1 mL ampoule concentrate for injection ◦ Oral > Liquid: 100 mg per mL ◦ Oral > Solid > capsule: 25 mg	Failure or rejection of transplanted organs or tissues

Cisplatin

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 10 mg per 10 mL; 20 mg per 20 mL; 50 mg per 50 mL; 100 mg per 100 mL ◦ Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL ◦ Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection	Other specified gliomas of brain Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx Malignant neoplasms of cervix uteri Malignant neoplasms of hypopharynx Malignant neoplasms of oropharynx Malignant neoplasms of nasopharynx Germ cell tumour of testis Osteosarcoma of bone or articular cartilage of unspecified sites Other specified malignant neoplasms of the ovary Malignant neoplasms of nasopharynx Other specified malignant neoplasms of bronchus or lung Unspecified malignant neoplasms of unspecified sites

Cladribine

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 1 mg per mL in 10 mL vial; 2 mg per mL in 5 mL vial	Langerhans cell histiocytosis

Cobimetinib

Section	Indications
Targeted therapies	Therapeutic equivalent to trametinib pour Other specified melanoma of skin

Crizotinib

Section	Indications
Targeted therapies ◦ Oral > Solid > capsule: 200 mg; 250 mg ◦ Oral > Solid: 200 mg; 250 mg	Anaplastic large cell lymphoma, ALK-positive Other specified malignant neoplasms of bronchus or lung

Cyclophosphamide

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection ◦ Oral > Solid > dosage form: 25 mg; 50 mg ◦ Oral > Solid: 25 mg tablet ◦ Parenteral > General injections > unspecified: 500 mg in vial powder for injection	Diffuse large B-cell lymphoma, not otherwise specified Chronic lymphocytic leukaemia or small lymphocytic lymphoma Plasma cell myeloma Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, not elsewhere classified Other specified gliomas of brain Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Rhabdomyosarcoma primary site Malignant neoplasms of breast Other specified malignant neoplasms of breast Unspecified malignant neoplasms of unspecified sites Hodgkin lymphoma Malignant trophoblastic neoplasms of placenta Follicular lymphoma Ewing sarcoma of bone or articular cartilage of unspecified sites Malignant neoplasms of kidney, except renal pelvis

Cytarabine

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per mL in vial ◦ Parenteral > General injections > unspecified: 100 mg in vial powder for injection	Acute myeloid leukaemia with recurrent genetic abnormalities Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, not elsewhere classified Myeloid leukaemia Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Langerhans cell histiocytosis Unspecified malignant neoplasms of unspecified sites

Dabrafenib

Section	Indications
Targeted therapies ◦ Oral > Solid: 50 mg; 75 mg	Other specified melanoma of skin

Dacarbazine

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection	Hodgkin lymphoma

Dactinomycin

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 500 µg in vial powder for injection	Rhabdomyosarcoma primary site Unspecified malignant neoplasms of unspecified sites Malignant trophoblastic neoplasms of placenta Ewing sarcoma of bone or articular cartilage of unspecified sites Malignant neoplasms of kidney, except renal pelvis

Daratumumab

Section	Indications
Immunomodulators ◦ Parenteral > General injections > IV: 100 mg per 5 mL; 400 mg per 20 mL	Plasma cell myeloma

Darbepoetin alfa

Section	Indications
Supportive medicines	Therapeutic equivalent to erythropoiesis-stimulating agents pour Drug-induced aplastic anaemia

Dasatinib

Section	Indications
Targeted therapies ◦ Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet	Chronic myelogenous leukaemia, BCR-ABL1-positive

Daunorubicin

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)	Acute myeloid leukaemia with recurrent genetic abnormalities Lymphoid leukaemia, not elsewhere classified Myeloid leukaemia

Dexamethasone

Section	Indications
Hormones and antihormones ◦ Oral > Liquid: 2 mg per 5 mL ◦ Oral > Solid: 2 mg; 4 mg ◦ Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosophate salt) ◦ Oral > Liquid: 2 mg per 5 mL (as sodium phosphate) ◦ Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base) ◦ Oral > Solid > tablet: 2 mg (as dexamethasone base); 4 mg (as dexamethasone base) ◦ Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base ◦ Oral > Solid > tablet: 4 mg (as dexamethasone base)	Anaplastic large cell lymphoma, ALK-negative Lymphoid leukaemia, not elsewhere classified Plasma cell myeloma Burkitt lymphoma including Burkitt leukaemia Anaplastic large cell lymphoma, ALK-positive

Docetaxel

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL	Malignant neoplasms of breast Other specified malignant neoplasms of breast Unspecified malignant neoplasms of unspecified sites Malignant neoplasms of prostate

Dostarlimab

Section	Indications
Immunomodulators ◦ Parenteral > General injections > IV: 50 mg per mL in 10 mL vial concentrate for solution for infusion	Other specified malignant neoplasms of corpus uteri

Doxorubicin

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection; 50 mg in vial (hydrochloride) powder for injection; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride) ◦ Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)	Diffuse large B-cell lymphoma, not otherwise specified Plasma cell myeloma Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, not elsewhere classified Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Rhabdomyosarcoma primary site Osteosarcoma of bone or articular cartilage of unspecified sites Kaposi sarcoma of unspecified primary site Malignant neoplasms of breast Other specified malignant neoplasms of breast Unspecified malignant neoplasms of unspecified sites Hodgkin lymphoma Follicular lymphoma Ewing sarcoma of bone or articular cartilage of unspecified sites Malignant neoplasms of kidney, except renal pelvis

Doxorubicin (as pegylated liposomal)

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 2 mg per mL in 10 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)	Kaposi sarcoma of unspecified primary site

Durvalumab

Section	Indications
Immunomodulators ◦ Parenteral > General injections > IV: 50 mg per mL in 2.4 mL vial concentrate solution for infusion; 50 mg per mL in 10 mL vial concentrate solution for infusion	Hepatocellular carcinoma of liver Malignant neoplasms of biliary tract, distal bile duct Malignant neoplasm of intrahepatic bile ducts Malignant neoplasms of gallbladder Malignant neoplasms of proximal biliary tract, cystic duct Other specified malignant neoplasms of bronchus or lung

Encorafenib

Section	Indications
Targeted therapies	Therapeutic equivalent to dabrafenib pour Other specified melanoma of skin

Enzalutamide

Section	Indications
Hormones and antihormones ◦ Oral > Solid: 40 mg	Therapeutic equivalent to abiraterone pour Malignant neoplasms of prostate Malignant neoplasms of prostate

Epoetin alfa

Section	Indications
Supportive medicines	Therapeutic equivalent to erythropoiesis-stimulating agents pour Drug-induced aplastic anaemia

Epoetin beta

Section	Indications
Supportive medicines	Therapeutic equivalent to erythropoiesis-stimulating agents pour Drug-induced aplastic anaemia

Erlotinib

Section	Indications
Targeted therapies ◦ Oral > Solid: 100 mg; 150 mg	Other specified malignant neoplasms of bronchus or lung

Erythropoiesis-stimulating agents

Section	Indications
Supportive medicines ◦ Parenteral > General injections > unspecified: 2000 IU per mL in vial (single-dose); 3000 IU per mL in vial (single-dose); 4000 IU per mL in vial (single-dose); 10000 IU per mL in vial (single-dose); 40000 IU per mL in vial (single-dose); 20000 IU per mL in vial (multiple-dose); 20000 IU per 2 mL in vial (multiple-dose)	Drug-induced aplastic anaemia

Etanercept

Section	Indications
Immunomodulators for non-malignant disease	Therapeutic equivalent to adalimumab pour Axial spondyloarthritis Therapeutic equivalent to adalimumab pour Crohn disease site Therapeutic equivalent to adalimumab pour Rheumatoid arthritis

Etoposide

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate) ◦ Oral > Solid: 100 mg capsule; 50 mg capsule ◦ Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule ◦ Oral > Solid: 100 mg capsule	Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, not elsewhere classified Myeloid leukaemia Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Germ cell tumour of testis Osteosarcoma of bone or articular cartilage of unspecified sites Other specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Unspecified malignant neoplasms of unspecified sites Hodgkin lymphoma Malignant trophoblastic neoplasms of placenta Retinoblastoma Ewing sarcoma of bone or articular cartilage of unspecified sites Malignant neoplasms of kidney, except renal pelvis

Everolimus

Section	Indications
Targeted therapies ◦ Oral > Solid > dispersible tablet: 2 mg; 3 mg; 5 mg ◦ Oral > Solid > tablet: 2.5 mg; 5 mg; 7.5 mg; 10 mg	Other specified gliomas of brain

Filgrastim

Section	Indications
Immunomodulators ◦ Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial	Acquired neutropaenia

Fingolimod

Section	Indications
Immunomodulators for non-malignant disease ◦ Oral > Solid: 0.25 mg; 0.5 mg	Relapsing-remitting multiple sclerosis

Fludarabine

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection ◦ Oral > Solid: 10 mg tablet (fludarabine phosphate)	Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Fluorouracil

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 50 mg per mL in vial ◦ Parenteral > General injections > IV: 50 mg per mL in 5 mL ampoule	Malignant neoplasms of nasopharynx Malignant neoplasms of rectum Malignant neoplasm metastasis in large intestine Malignant neoplasms of breast Malignant neoplasms of colon Unspecified malignant neoplasms of unspecified sites

Flutamide

Section	Indications
Hormones and antihormones	Therapeutic equivalent to bicalutamide pour Malignant neoplasms of prostate

Fulvestrant

Section	Indications
Hormones and antihormones ◦ Parenteral > General injections > IV: 250 mg per 5 mL	Malignant neoplasms of breast

Gefitinib

Section	Indications
Targeted therapies	Therapeutic equivalent to erlotinib pour Other specified malignant neoplasms of bronchus or lung

Gemcitabine

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection	Other specified carcinomas of ovary Other specified malignant neoplasms of bronchus or lung

Golimumab

Section	Indications
Immunomodulators for non-malignant disease	Therapeutic equivalent to adalimumab pour Axial spondyloarthritis Therapeutic equivalent to adalimumab pour Crohn disease site Therapeutic equivalent to adalimumab pour Rheumatoid arthritis

Goserelin

Section	Indications
Hormones and antihormones	Therapeutic equivalent to leuprorelin pour Malignant neoplasms of breast Therapeutic equivalent to leuprorelin pour Malignant neoplasms of prostate

Hydrocortisone

Section	Indications
Hormones and antihormones ◦ Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)	Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia Unspecified malignant neoplasms of unspecified sites

Hydroxyurea (hydroxycarbamide)

Section	Indications
Cytotoxic medicines ◦ Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g ◦ Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg	Squamous cell carcinoma of oropharynx Chronic myeloid leukaemia, not elsewhere classified

Ibrutinib

Section	Indications
Targeted therapies ◦ Oral > Solid: 140 mg	Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Ifosfamide

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection ◦ Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection	Burkitt lymphoma including Burkitt leukaemia Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Rhabdomyosarcoma primary site Osteosarcoma of bone or articular cartilage of unspecified sites Germ cell tumour of testis Other specified malignant neoplasms of the ovary Unspecified malignant neoplasms of unspecified sites Ewing sarcoma of bone or articular cartilage of unspecified sites Malignant neoplasms of kidney, except renal pelvis

Imatinib

Section	Indications
Targeted therapies ◦ Oral > Solid: 100 mg; 400 mg	B lymphoblastic leukaemia or lymphoma with t(9:22) (q34;q11.2); BCR-ABL1 Chronic myeloid leukaemia, not elsewhere classified Gastrointestinal stromal tumour of unspecified gastrointestinal sites

Infliximab

Section	Indications
Immunomodulators for non-malignant disease	Therapeutic equivalent to adalimumab pour Axial spondyloarthritis Therapeutic equivalent to adalimumab pour Crohn disease site Therapeutic equivalent to adalimumab pour Rheumatoid arthritis

Ipilimumab

Section	Indications
Immunomodulators ◦ Parenteral > General injections > IV: 5 mg per mL in 10 mL vial concentrate for solution for infusion; 20 mg per mL in 40 mL vial concentrate for solution for infusion	Renal cell carcinoma of kidney, except renal pelvis Squamous cell carcinoma of oesophagus Melanoma of skin Other specified malignant neoplasms of bronchus or lung

Irinotecan

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial	Rhabdomyosarcoma primary site Malignant neoplasm metastasis in large intestine Malignant neoplasms of kidney, except renal pelvis

Lenalidomide

Section	Indications
Immunomodulators ◦ Oral > Solid: 25 mg	Plasma cell myeloma

Lenvatinib

Section	Indications
Targeted therapies ◦ Oral > Solid > capsule: 4 mg; 10 mg	Renal cell carcinoma of kidney, except renal pelvis

Leuprorelin

Section	Indications
Hormones and antihormones ◦ Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe	Malignant neoplasms of breast Malignant neoplasms of prostate

Lisocabtagene maraleucel

Section	Indications
Antineoplastics and supportive medicines	Therapeutic equivalent to axicabtagene ciloleucel pour Diffuse large B-cell lymphomas

Melphalan

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 50 mg in vial powder for injection ◦ Oral > Solid: 2 mg	Plasma cell myeloma

Mercaptopurine

Section	Indications
Cytotoxic medicines ◦ Oral > Liquid: 20 mg per mL ◦ Oral > Solid: 50 mg tablet	Lymphoid leukaemia, not elsewhere classified Acute myeloid leukaemia with recurrent genetic abnormalities Langerhans cell histiocytosis Unspecified malignant neoplasms of unspecified sites

Mesna

Section	Indications
Supportive medicines ◦ Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 2 mL ampoule ◦ Oral > Solid > tablet: 400 mg; 600 mg ◦ Oral > Other: 600 mg ◦ Oral > Solid > tablet: 400 mg ◦ Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule ◦ Oral > Solid: 400 mg; 600 mg	Rhabdomyosarcoma primary site Germ cell tumour of testis Other specified malignant neoplasms of the ovary Osteosarcoma of bone or articular cartilage of unspecified sites Unspecified malignant neoplasms of unspecified sites Ewing sarcoma of bone or articular cartilage of unspecified sites Malignant neoplasms of kidney, except renal pelvis Burkitt lymphoma including Burkitt leukaemia

Methotrexate

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection ◦ Oral > Solid: 2.5 mg (as sodium salt) ◦ Parenteral > General injections > IV: 50 mg in vial (as sodium salt)	Lymphoid leukaemia, not elsewhere classified Acute myeloid leukaemia with recurrent genetic abnormalities Burkitt lymphoma including Burkitt leukaemia Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Langerhans cell histiocytosis Osteosarcoma of bone or articular cartilage of unspecified sites Malignant neoplasms of breast Unspecified malignant neoplasms of unspecified sites Malignant trophoblastic neoplasms of placenta
Immunomodulators for non-malignant disease ◦ Parenteral > General injections > SC: pre-filled syringe in multiple strengths	Crohn disease site Psoriatic arthritis

Methylprednisolone

Section	Indications
Hormones and antihormones ◦ Parenteral > General injections > IV: 40 mg in vial (as sodium succinate); 125 mg in vial (as sodium succinate) ◦ Parenteral > General injections > IV: 40 mg in vial (as sodium succinate) powder for injection; 125 mg in vial (as sodium succinate) powder for injection	Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, not elsewhere classified

Nilotinib

Section	Indications
Targeted therapies ◦ Oral > Solid > capsule: 150 mg; 200 mg	Chronic myelogenous leukaemia, BCR-ABL1-positive

Nilutamide

Section	Indications
Hormones and antihormones	Therapeutic equivalent to bicalutamide pour Malignant neoplasms of prostate

Nivolumab

Section	Indications
Immunomodulators ◦ Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion ◦ Parenteral > General injections > IV: 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion; 10 mg per mL in 24 mL vial concentrate solution for infusion ◦ Parenteral > General injections > IV: 10 mg per mL in 24 mL vial concentrate solution for infusion; 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion	Therapeutic equivalent to pembrolizumab pour Melanoma of skin Melanoma of skin Renal cell carcinoma of kidney, except renal pelvis Squamous cell carcinoma of oesophagus Adenocarcinoma of oesophagogastric junction Adenocarcinoma of stomach Other specified malignant neoplasms of bronchus or lung

Osimertinib

Section	Indications
Targeted therapies ◦ Oral > Solid: 40 mg (as mesylate); 80 mg (as mesylate)	Other specified malignant neoplasms of bronchus or lung

Oxaliplatin

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial	Malignant neoplasm metastasis in large intestine Malignant neoplasms of colon

Paclitaxel

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 6 mg per mL	Malignant neoplasms of cervix uteri Kaposi sarcoma of unspecified primary site Other specified malignant neoplasms of the ovary Malignant neoplasms of nasopharynx Other specified carcinomas of ovary Other specified malignant neoplasms of bronchus or lung Other specified malignant neoplasms of breast Malignant neoplasms of breast

Palbociclib

Section	Indications
Targeted therapies ◦ Oral > Solid: 75 mg; 100 mg; 125 mg	Other specified malignant neoplasms of breast

Panitumumab

Section	Indications
Targeted therapies ◦ Parenteral > General injections > IV: 20 mg per mL in 5 mL vial concentrate for solution for infusion; 20 mg per mL in 20 mL vial	Other specified malignant neoplasms of large intestine

Pegaspargase

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection	Lymphoid leukaemia, not elsewhere classified

Pegfilgrastim

Section	Indications
Immunomodulators ◦ Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe	Acquired neutropaenia

Pembrolizumab

Section	Indications
Immunomodulators ◦ Parenteral > General injections > IV: 25 mg per mL in 4 mL vial ◦ Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion ◦ Parenteral > General injections > IV: 25 mg per mL in 4 mL vial powder for injection	Melanoma of skin Other specified malignant neoplasms of large intestine Malignant neoplasms of cervix uteri Adenocarcinoma of stomach Malignant neoplasms of oesophagogastric junction Squamous cell carcinoma of hypopharynx and variants Squamous cell carcinoma of other or ill-defined sites in the lip, oral cavity or pharynx Squamous cell carcinoma of oropharynx Squamous cell carcinoma of nasopharynx Therapeutic equivalent to nivolumab pour Melanoma of skin Renal cell carcinoma of kidney, except renal pelvis Carcinoma of breast, specialised type Squamous cell carcinoma of oesophagus Other specified malignant neoplasms of bronchus or lung

Pertuzumab

Section	Indications
Targeted therapies ◦ Parenteral > General injections > IV: 240 mg per 14 mL in vial concentrated solution	Carcinoma of breast, specialised type

Prednisolone

Section	Indications
Hormones and antihormones ◦ Oral > Liquid: 5 mg per mL ◦ Oral > Solid: 5 mg; 25 mg	Lymphoid leukaemia, not elsewhere classified Diffuse large B-cell lymphoma, not otherwise specified Chronic lymphocytic leukaemia or small lymphocytic lymphoma Plasma cell myeloma Burkitt lymphoma including Burkitt leukaemia Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Langerhans cell histiocytosis Unspecified malignant neoplasms of unspecified sites Hodgkin lymphoma Malignant neoplasms of prostate Follicular lymphoma

Prednisone

Section	Indications
Hormones and antihormones	Therapeutic equivalent to prednisolone pour Lymphoid leukaemia, not elsewhere classified Therapeutic equivalent to prednisolone pour Diffuse large B-cell lymphoma, not otherwise specified Therapeutic equivalent to prednisolone pour Chronic lymphocytic leukaemia or small lymphocytic lymphoma Therapeutic equivalent to prednisolone pour Plasma cell myeloma Therapeutic equivalent to prednisolone pour Anaplastic large cell lymphoma, ALK-negative Therapeutic equivalent to prednisolone pour Anaplastic large cell lymphoma, ALK-positive Therapeutic equivalent to prednisolone pour Langerhans cell histiocytosis Therapeutic equivalent to prednisolone pour Hodgkin lymphoma Therapeutic equivalent to prednisolone pour Malignant neoplasms of prostate Therapeutic equivalent to prednisolone pour Follicular lymphoma

Procarbazine

Section	Indications
Cytotoxic medicines ◦ Oral > Solid: 50 mg (as hydrochloride) ◦ Oral > Solid > capsule: 50 mg (as hydrochloride)	Unspecified malignant neoplasms of unspecified sites Hodgkin lymphoma

Rasburicase

Section	Indications
Supportive medicines ◦ Parenteral > General injections > IV: 1.5 mg in vial powder and 1 mL solvent for solution; 7.5 mg in vial powder and 5 mL solvent for solution	Tumour lysis syndrome

Realgar-indigo naturalis formulation

Section	Indications
Cytotoxic medicines ◦ Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)	Acute myeloid leukaemia with recurrent genetic abnormalities

Ribociclib

Section	Indications
Targeted therapies	Therapeutic equivalent to palbociclib pour Other specified malignant neoplasms of breast

Rituximab

Section	Indications
Targeted therapies ◦ Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial	Diffuse large B-cell lymphoma, not otherwise specified Chronic lymphocytic leukaemia or small lymphocytic lymphoma Burkitt lymphoma including Burkitt leukaemia Follicular lymphoma

Tacrolimus

Section	Indications
Immunomodulators for non-malignant disease ◦ Parenteral > General injections > IV: 5 mg per mL in 1 mL vial ◦ Oral > Liquid: 0.2 mg granules for oral suspension; 1 mg granules for oral suspension ◦ Oral > Solid: 0.5 mg (immediate-release); 0.75 mg (immediate-release); 1 mg (immediate-release); 2 mg (immediate-release); 5 mg (immediate-release)	Failure or rejection of transplanted organs or tissues

Tamoxifen

Section	Indications
Hormones and antihormones ◦ Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)	Malignant neoplasms of breast Other specified malignant neoplasms of breast

Temozolomide

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 100 mg in vial powder for injection ◦ Oral > Solid > capsule: 5 mg; 20 mg; 100 mg; 140 mg; 180 mg; 250 mg	Other specified gliomas of brain Neuroblastoma, NOS Unspecified malignant neoplasms of unspecified sites Ewing sarcoma of bone or articular cartilage of unspecified sites

Thalidomide

Section	Indications
Immunomodulators ◦ Oral > Solid: 50 mg	Plasma cell myeloma

Tioguanine

Section	Indications
Cytotoxic medicines ◦ Oral > Solid: 40 mg	Lymphoid leukaemia, not elsewhere classified

Tisagenlecleucel

Section	Indications
Antineoplastics and supportive medicines	Therapeutic equivalent to axicabtagene ciloleucel pour Diffuse large B-cell lymphomas

Tislelizumab

Section	Indications
Immunomodulators ◦ Parenteral > General injections > IV: 100 mg per 10 mL ◦ Parenteral > General injections > IV: 100 mg per 10 mL concentrate for solution for infusion ◦ Parenteral > General injections > IV: 100 mg per 10 mL contentrate for solution for infusion	Malignant neoplasms of urinary tract Squamous cell carcinoma of oesophagus Other specified malignant neoplasms of bronchus or lung Hodgkin lymphoma

Toripalimab

Section	Indications
Immunomodulators ◦ Parenteral > General injections > IV: 240 mg per 6 mL in vial	Squamous cell carcinoma of oesophagus Malignant neoplasms of nasopharynx

Trametinib

Section	Indications
Targeted therapies ◦ Oral > Solid: 0.5 mg; 2 mg	Other specified melanoma of skin

Trastuzumab

Section	Indications
Targeted therapies ◦ Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection	Carcinoma of breast, specialised type

Trastuzumab emtansine

Section	Indications
Targeted therapies ◦ Parenteral > General injections > IV: 100 mg in vial powder for injection; 160 mg in vial powder for injection	Carcinoma of breast, specialised type

Tremelimumab

Section	Indications
Immunomodulators ◦ Parenteral > General injections > IV: 20 mg per mL in 1.25 mL vial concentrate solution for infusion; 20 mg per mL in 15 mL vial concentrate solution for infusion	Hepatocellular carcinoma of liver Other specified malignant neoplasms of bronchus or lung

Triptorelin

Section	Indications
Hormones and antihormones	Therapeutic equivalent to leuprorelin pour Malignant neoplasms of breast Therapeutic equivalent to leuprorelin pour Malignant neoplasms of prostate

Vemurafenib

Section	Indications
Targeted therapies	Therapeutic equivalent to dabrafenib pour Other specified melanoma of skin

Vinblastine

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate) ◦ Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)	Other specified gliomas of brain Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Langerhans cell histiocytosis Kaposi sarcoma of unspecified primary site Germ cell tumour of testis Other specified malignant neoplasms of the ovary Unspecified malignant neoplasms of unspecified sites Hodgkin lymphoma

Vincristine

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate) ◦ Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)	Other specified gliomas of brain Diffuse large B-cell lymphoma, not otherwise specified Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, not elsewhere classified Langerhans cell histiocytosis Kaposi sarcoma of unspecified primary site Rhabdomyosarcoma primary site Hodgkin lymphoma Unspecified malignant neoplasms of unspecified sites Malignant trophoblastic neoplasms of placenta Follicular lymphoma Ewing sarcoma of bone or articular cartilage of unspecified sites Retinoblastoma Malignant neoplasms of kidney, except renal pelvis

Vinorelbine

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial ◦ Oral > Solid > capsule: 20 mg; 30 mg; 80 mg ◦ Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial	Rhabdomyosarcoma primary site Other specified malignant neoplasms of bronchus or lung Other specified malignant neoplasms of breast

Zanubrutinib

Section	Indications
Targeted therapies ◦ Oral > Solid: 80 mg ◦ Oral > Solid > capsule: 80 mg	Mantle cell lymphoma Therapeutic equivalent to ibrutinib pour Chronic lymphocytic leukaemia or small lymphocytic lymphoma Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Zoledronic acid

Section	Indications
Supportive medicines ◦ Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle	Malignant neoplasm metastasis in bone or bone marrow